Last reviewed · How we verify
BP102, paclitaxel, carboplatin
BP102, paclitaxel, carboplatin is a Chemotherapy combination (taxane + platinum agent) Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Non-small cell lung cancer (phase 3), Potentially other solid tumors (under investigation).
BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells.
BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells. Used for Non-small cell lung cancer (phase 3), Potentially other solid tumors (under investigation).
At a glance
| Generic name | BP102, paclitaxel, carboplatin |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | Microtubules (paclitaxel); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BP102 combines paclitaxel, a microtubule-stabilizing agent that prevents cell division, with carboplatin, a platinum-based DNA crosslinker that causes irreparable DNA damage. The nanoparticle albumin-bound formulation of paclitaxel enhances tumor penetration and reduces systemic toxicity compared to conventional formulations. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer (phase 3)
- Potentially other solid tumors (under investigation)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Fatigue
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (PHASE3)
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (PHASE3)
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (PHASE2)
- Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (PHASE2)
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP102, paclitaxel, carboplatin CI brief — competitive landscape report
- BP102, paclitaxel, carboplatin updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about BP102, paclitaxel, carboplatin
What is BP102, paclitaxel, carboplatin?
How does BP102, paclitaxel, carboplatin work?
What is BP102, paclitaxel, carboplatin used for?
Who makes BP102, paclitaxel, carboplatin?
What drug class is BP102, paclitaxel, carboplatin in?
What development phase is BP102, paclitaxel, carboplatin in?
What are the side effects of BP102, paclitaxel, carboplatin?
What does BP102, paclitaxel, carboplatin target?
Related
- Drug class: All Chemotherapy combination (taxane + platinum agent) drugs
- Target: All drugs targeting Microtubules (paclitaxel); DNA (carboplatin)
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (phase 3)
- Indication: Drugs for Potentially other solid tumors (under investigation)
- Compare: BP102, paclitaxel, carboplatin vs similar drugs
- Pricing: BP102, paclitaxel, carboplatin cost, discount & access